Treatment of Ovarian Cancer in Mucinous Neoplasm or Carcinoma of the Ovary
Clinical Scenario
Mucinous neoplasms and mucinous carcinoma of the ovary form a distinct histological subtype with clinical behaviour that differs from more common epithelial ovarian cancers, requiring tailored treatment strategies.
Specific Population
This protocol applies to patients with confirmed mucinous neoplasm or mucinous carcinoma of the ovary, including those presenting with recurrent disease.
Treatment Approach (Partial Overview)
Recurrence in mucinous carcinoma of the ovary is addressed with specific chemotherapy-based regimens. Treatment selection is guided by platinum sensitivity, with distinct combination options available for each clinical setting.
Full regimen details, complete sequencing, and all dosing specifications are available in the structured protocol below.
References
- Mucinous neoplasms of the ovary
- FOLFIRI ± Bevacizumab (category 2B)
- Fluorouracil/Leucovorin/Oxaliplatin ± Bevacizumab (category 2B for Bevacizumab)
- Capecitabine/Oxaliplatin ± Bevacizumab (category 2B for Bevacizumab)
View source ↗